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A large part of medical practice no matter how general or specialised, is 
complicated by two problems, viz. : 
1) The degree to which treatments are specific (the placebo problem) and, 
2) The extent to which treatments are implemented (the compliance or ad-
herence problem). 
There has been an upsurge of interest in these two aspects of medical management 
in recent years, paralleling the increased prominence given to social and epide-
miological issues in all branches of medicine, a fuller understanding of which 
is essential prior to the planning and implementation of Health Services at 
national and community level. The geometrically escalating cost of providing 
medical services, consequent upon recent inflationary economic trends, has high-
lighted the need for realistic cost-benefit analyses of all treatment modalities. 
It is obvious that any stratagems which improve the utilisation of the currently 
available Health Services, at minimal extra cost, such as the improvement of 
patient compliance, will lead to an optimisation of any such cost-benefit ratios. 
(Underlying this statement is, of course, the assumption that compliance by the 
patient with his treatment regimen is accepted by the medical fraternity as being 
unequivocally essential). With these general provisos in mind, it was decided 
to include the assessment of compliance with medication regimens as a subsection 
of the study into major psychiatric illness undertaken by the Medical Research 
Council Unit for Social Psychiatry, at Groote Schuur Hospital. This study 
entails the full medical, psychiatric and social assessment of a cohort of 
patients admitted to Valkenberg Hospital, and their follow up for a further five 
years after the initial admission. 
The aims of the Compliance Study are multiple and sequential, namely ; 
1) The quantitative assessment of the percentages of patients, within and 
across the various race groups, who comply with their medication regimens 
following discharge from the hospital. 
2) The aualitative assessment of the reasons given by patients and family 
members for poor compliance, where it exists. 
3) The correlation of good or poor compliance with other patients variables 
such as age, sex, race and diagnosis. 
4) The assessment of the role of compliance in subsequent relapse and re-
admission. 
5) Ultimately, it is hoped that these findings may be or practical benefit 
in improving the treatment of the population concerned. 
As the study is still in progress, this dissertation is limited to the initial 
stages outlined, namely the quantitative assessment of compliance across the 
various race groups, the reasons ascertained for poor compliance, and discussion 
of significant differences where noted. 
To begin with, a brief overview will be given of ~he scope and definition of the 
compliance problem as seen on a global scale. Thereafter the methodology, 
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results and conclusions of the local study are presented. 
LITERATURE REVIEW 
As with other areas of medical knowledge, information on compliance is roughly 
doubling in amount every five years. Haynes and Sackett (1976) developed an 
annotated bibliography of 246 articles written up to 1973. 
PERIOD NUMBER OF PUBLICATIONS 
1956 - 1960 12 
1961 - 1965 45 
1966 - 1970 79 
1971 - 1975 133 
The definitive overview with special reference to Psychiatry is generally held to 
be that by Blackwell (1976). 
Haynes and Sackett's book "Compliance with therapeutic Regimens" covers every 
aspect of Medical Practice, but lacks the depth and sophistication of the 
Blackwell article. 
The most accessible and comprehensive general review article is probably that by 
Marston (1970) that appeared in a Nursing Journal acknowledging, perhaps, the role 
of this profession as the traditional bearers of the compliance problem. 
Defining the term "compliance" is not easy. The list of medical subject headings 
in the Index Medicus has only included the category "Patient Compliance" since 
1975. 
Before then, the major descriptive term was "patient drop-out". (Interestingly, 
the word "compliance" has no counterpart in Afrikaans, Dutch or German where, 
perhaps, the Calvinist ethic takes patient co-operation for granted). In 
America the coercive connotation of the word "compliance" has lead to an increased 
use of the word "adherence", supposedly to acknowledge the right of the patient to 
follow or ignore his physicians advice. To all intents and purposes, the terms 
can be considered synonymous. 
The 1st International Congress on Patient Counselling defined the problem as 
follows; "When a patient does not follow the treatment schedules suggested to 
him by the physician, for the management of some illness, the patient can be 
described as non-compliant". 
This definition is both unduly restrictive and inadequately descriptive. Com-
pliance encompasses a wide variety of behaviours on the part of the patient :-
1) Failure to enter a treatment programme 
2) Premature termination of therapy 
3) Incomplete implementation of instructions 
- including those pertaining to prescribed medications. 
A further problem arises when trying to define the boundary between good and bad 
compliance, e.g. When is the patient to be considered non-compliant? Is it 
when he takes the tablets incorrectly, i.e. either too infrequently or too often 
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by his own conscious designs, or is it only non-compliance if the mistakes are 
due to ignorance? Or is it both? How wrong must the patient be in taking 
his tablets to be considered non-compliant? What should we make of the patient 
who takes his neuroleptic tablet twice a day instead of three times? This type 
of question, which usually begets yet another, is not merely nit-picking, but 
highlights the strict criteria needed for a scientific study, the lack of which 
has flawed the methodology of many retrospective studies. In only half of the 
studies reviewed by Haynes and Sackett was the term "compliance", described in 
a manner adequate to permit independent replication. 
The criteria for our local study are discussed later. 
Of the 320 articles listed in the 2 major sources (Haynes and Sackett, 1976, 
Pothier, 1975), 55 (17%) deal directly with psychiatry. Almost every kind of 
patient has been studied, including alcoholics, (Rosenberg, 1973), narcotic 
addicts, (Adams, 1971), psychotherapy clients, (Heine, 1960) and (Seeman, 1974), 
depressed, anxious and schizophrenic adults, (Park, 1964, Harris, 1976, Hogarty, 
1973), and disturbed or retarded children. 
(Wikler, 1974). 
settings :-
Compliance problems have been evaluated in a variety of 
1) In-patient Units (Hare & Willcox, 1967) 
2) Out-patient Clinics (Carr & Whittenbaugh, 1968) 
3) Community Mental Health Centres (Kline & King, 1973) 
4) Halfway Houses (Orford, 1974) 
5) Home visits (Nicholson, 1967). 
The studies quoted attend variously to the quantitative aspects of compliance 
i.e. the percentages of compliers vs. non-compliers, and the qualitative aspects 
such as the reasons for good or bad compliance, and the relationships to other 
independent variables. 
Factors leading to better compliance have been known for a long time, the most 
important of which are :-
1) Improved doctor-patient relationship 
2) Same doctor being seen at each visit 
3) Improved explanation by doctor of the reasons for, and functions of, 
the tablets 
4) Simpler treatment regimens, especially the reduction of the number of 
doses per day 
5) Decreased number of types of medication 
6) Shorter clinic waiting time 
7) Social supervision (Compliance poor in patients living alone) 
8) Compliance is better for acute illnesses where immediate benefit is more 
tangible than the distant consequences of those illnesses treated 
prophylactically. Notably hypertension, hyperlipidaemi3 and bipolar 
affective disorder 
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9) Some studies have shown that a good prognosis is associated with 
better compliance. 
It must be again stressed that these factors have long been known, it is their 
implementation that remains the problem. Many studies have shown that there is 
no stereotype "drug defaulter". The interaction between patient and physician 
is more complex than that opinion often expressed by doctors, namely, that certain 
patients have "unco-operative personalities". 
McClellan and Cowan (1970) showed that even skilled psychiatrists cannot 
accurately predict which patient will or will not comply. The psychiatrists 
were wrong 20% of the time and interestingly, 71% of their mistakes were in the 
direction of believing that patients were not complying when in fact they were. 
Blackwell (1976) maintains that the crux of the problem lies in the dynamics of 
being cared for. Motivation and patients' attitudes to illness are secondary. 
Cultural concepts of illness are central to how the patient views the physician, 
let alone how he views the treatment. 
Raskin (1961) offers a pragmatic dynamic interpretation of non-compliance, which 
is interpreted as a way of denying anxiety, expressing hostility or challenging 
the roles in the game. 
ERRORS in drug adherence may be categorised into 4 groups (Malahy, 1966) : 
1) Errors of omission 
2) Errors of purpose 
3) Errors of dosage 
4) Mistakes in timing or sequence. 
The literature is restricted mainly to the study of errors of omission. Most 
studies have relied on spot checks as opposed to repeated observations, as the 
problem of accurate assessment is complicated by the "Hawthorne effect" : namely 
that, with increasing attention being shown by investigators, the compliance 
problem decreases and the placebo effect increases. (Blackwell, 1976). 
Consequently, most of the conclusions reported in the literature are based on 
findings in which a single observation suggests that a significant portion, or 
all of the medication has been omitted. 
METHODS OF MEASUREMENT 
These can be subdivided into :-
1) Subjective e.g. asking the patient or family member about compliance. 
2) Objective e.g. testing a body fluid for the presence of a drug metabolite. 
There are 4 frequently used methods of assessing compliance with medication 
regimens. 
1) Patient and/or family interrogation. 
This method is often unreliable. Willcox (1965) found that 31% of 
out-patients claiming to be taking ~heir drugs. had negative urine tests. 
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2) Tablet estimates (Pill counts). 
Frequently misleading because there is no assurance that what has left 
the bottle was taken by the patient. 
3) Drug markers. 
Inert harmless chemical markers that show up in various body fluids 
e.g. RIBOFLAVIN was previously used as a urine marker. 
4) Direct drug or metabolite detection. 
The most reliable method, especially if applied without prior warning. 
Common examples include the measurement of serum concentrations of lithium, 
anticonvulsants and digitalis. 
The presence of phenothiazine metabolites can be detected in the urine using 
the Forrest reagent. This is a reliable colorimetric test developed by Drs. 
Fred and Irene Forrest a husband and wife team of psychiatrist and biochemist. 
(Discussed in detail in Appendix B). 
Utilising these various methods either singly or in combination, non-compliance 
is reported in between 25 and 50 percent of out-patients and a variable smaller 
number of in-patients. As well as quoting numbers, the literature also debates 
the significance of non-compliance with regards to morbidity in schizophrenia, 
the pros and cons of self regulation of dosage (Uhlenhuth, 1965) the economic 
wastage, hazards to health and the possible distortion of therapeutic trials. 
(Porter, 1969). 
No comparable studies have been performed in South Africa, hence the need to 
include compliance assessment in the MRC Unit Valkenberg Study. 
VALKENBERG HOSPITAL COMPLIANCE STUDY - METHODOLOGY 
A questionaire (Appendix A) was devised for administration by research 
assistants at unannounced follow up home visits, made approximately 6 months 
after the patient was discharged from hospital. 
The study population consisted of the patients collected in the Valkenberg 
cohort, i.e. staggered sequential admissions to Valkenberg Hospital for a six 
month period in 1981. 
The cohort was subdivided along ethnic lines and consisted of 
160 Whites 
150 Coloureds 
150 Blacks (mainly Xhosa) 
The population followed up was obviouslv fewer in number than the original 
cohort due to various factors : 
1) Patients lost to follow up 
2) Patients who died in hospital 
3) Patients who remained in hospital 
4) Patients completely discharged on no treatment. 
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The questionaire itself is straightforward, and for the most part requires 
simple yes or no answers. 
However, certain aspects deserve comment. It was initially decided to rate 
responses on a 3 point scale, in keeping with the 3 point scale used in other 
data gathering implements such as the PSE. It was also initially deemed 
important to assess the 'grey area' between the two extremes possible in 
answering such questions as No. 6. "Does the patient/family know what the 
tablets are for?" 






However, retrospectively it was realised that the 3 point scale was a methodo-
logical error that introduced problems into the statistical analysis of the 
results. 
This initial part of the follow up study is not severely affected, but for the 
second part (i.e. the correlation of good or poor compliance with other patient 
variables) it is proving necessary to include the middle rating category, es-
pecially where compliance was rated as "moderate" (Questions 7 + 9), into either 
the good or poor categories. On clinical grounds it was decided to include the 
"moderate" category with "poor", though this is not completely satisfactory as 
the significance of intermittent medication for a condition such as schizophrenia 
or an anxiety state is not as demonstrably unequivocally inadvisable as would be 
the case in conditions such as epilepsy or lithium controlled Bipolar Affective 
Disorder. 
The questionaire provides information on the following aspects of post discharge 
treatment. 
1) Type of medication 
2) Awareness of appointments 
3) Supervision of medication 
Modecate 
Lithium 
Phenothiazines other than Modecate. 
4) Awareness of medication regimen 
5) Awareness of medication function 
6) Compliance with medication regimen (see below) 
7) Reasons given for poor compliance. 
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METHODS USED TO ASSESS COMPLIANCE 
Unlike all the studies reviewed in the literature, this study used three 
separate measures of compliance (Question 7) and provided an opportunity for the 
research worker to make his or her own subjective rating based on the previous 
measures plus their own impressions and feelings in general about the patient and 
family (Question 9). Multiple assessment methods were included so that inter-
rating reliability could be assessed, specifically the correlation between the 
subjective measure (family opinion) and the objective measure (Urine test). It 
was also hoped that perhaps one method would emerge as the most reliable and 
easiest to undertake, and that this superior assessment method could then be 
utilised in any future studies or incorporated into the current out-patient 
services. It is noteworthy that none of the studies reviewed promote any one 
method over the others. Whereas the family's opinion was sought, it was later 
realised that our failure to include a question asking the patients themselves 
about their compliance, was an unfortunate omission. 
URINE TESTING 
The research workers were supplied with 10 ml test tubes each containing 1 ml of 
the General Forrest Reagent (Reviewed in detail in Appendix B). On the addition 
of an equal amount of urine containing phenothiazine (and Imipramine) metabolites, 
the solution turns a variable shade of blue, proving that a clinically significant 
dosage of phenothiazine has been ingested in the past three days. The test does 
not allow for the potency of the drug administered, or indicate its anti-psychotic 
activity in any way. Fluphenazine depot (Modecate) 25 mgs monthly will not in-
duce a colour change, but doses of 25 mgs weekly may cause the lightest shade of 
blue to appear. Overall there were no problems encountered in using the reagent 
which was initially tested in a Pilot study in the acute admission wards at 
Valkenberg Hospital. Urine samples were obtained from 10 psychotic patients 
receiving a variety of phenothiazines including Chlorpromazine, Perphenazine and 
Trifluoperazine in normal doses. A further five samples were collected froffi 
nursing and medical staff. In every case the Forrest reagent reacted appro-
priately. Of special importance was the absence of any false negatives in the 
patient sample as the problem of possible drug rejection or non-absorption was 
not taken into account in planning the study, and is worthy of further assessment 
at a later stage (Wilson, J.D., 1967). 
RESULTS 
There were no problems of note experienced by the field workers, with only 5 
patients unexplainably lost to follow up. The data from the first 6 - monthlv 
follow-up was available by June, 1983. and the first computer print-out of results 
was received in August, 1983. 
This original print-out revealed many coding and tabulating errors and necessi-
tated extensive revision. The final corrected working print-out was available 
by January, 1984. Significance levels for differences present within a parti-
cular system i.e. across the 3 race groups, were supplied with the print-out. 
Significance levels between any 2 race groups were calculated individually where 
necessary using a suitably programmed desk-top calculator. Differences were 
taken to be significant at the level P L0,05. 
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The results are presented under the following headings 
TABLE I MEDICATION TYPE 
TABLE II RECEIPT AND SUPERVISION OF MEDICATION 
TABLE III AWARENESS OF TREATMENT AND REGIMEN 
TABLE IV COMPLIANCE 1. FAMILY OPINION 
TABLE V COMPLIANCE 2. PILL COUNT 
TABLE VI COMPLIANCE 3. URINE TEST 
TABLE VII COMPLIANCE 4. INTERVIEWER ASSESSMENT 
TABLE VIII REASONS FOR NOT COMPLYING 
Discussion and comment immediately follows each table. 
RESULTS 




Whole cohort w C B Differences 
Modecate 32 24 32 40 B : w (p 0,05) 
Lithium 8 15 6 3 w : B (p 0,01) 
~} 
Phenothiazine 53 38 60 59 C & B : w (p 0,005) 
All pills 92 90 94 91 NS 
* Includes Modecate and other phenothiazines; excludes Modecate only. 
TABLE I 
For the cohort as a whole, almost all are on some type of oral medication. 
Just over half are on a phenothiazine and a third on Modecate. 





Significantly more Blacks (40%) are on Modecate than Whites (24%). 
The percentage of Coloureds on Modecate is in between (32%) but is not 
significantly different from either B or W. 
Lithium : 
The prescription of Lithium shows the reverse trend i.e. significantly more 
Whites (15%) compared with Blacks (3%). Once again the figure for 




Significantly more Coloureds and Blacks were prescribed phenothiazines 
(60% & 59%) than Whites (38%). 
0 
Pills : 
No significant differences. 
DISCUSSION 
92% of people who leave hospital are on pills. This has important implications 
as regards t~e provision of out-patient services. 
1) Pharmacies are needed. 
2) Pharmacy staff, professional and clerical, are needed. 
3) Logistical problems arise regarding the implementation of a distribution 
system to supply medication to country areas. 
(It should be mentioned here that not one patient referred to a District 
Nurse, had ever been visited at home, or contacted to attend the local 
clinic. This problem needs special attention). 
The differences between the races in the type of medication prescribed might 
reflect any of 3 things : 
1) Diagnostic differences between the races, (possibly more Blacks suffer from 
that type of illness for which Modecate is routinely prescribed). 
2) Diagnostic ability or policy of doctors may vary according to the race 
group of the patient. 
3) Prescription policy of doctors. Even if diagnoses are the same, more 
Blacks may be receiving Modecate because of previously unverified but 
nonetheless generally accepted beliefs that "they don't comply". There 
is also a common myth that Blacks "prefer injections" - this has also never 
been tested. Furthermore it is accepted by staff in the acute admission 
wards, that toxins - particularly dagga and Mandrax, play a greater role in 
the illnesses of Coloureds and Blacks than they do in Whites. Hence 
Modecate is almost routinely given so that the patient "has something in 
him next time he smokes". 
It is hoped that many of these speculations that arise from the different 
types of medication within the various race groups will be answered during 
the second phase of the follow-up study i.e. when compliance is correlated 




Receipt of Medication 
TABLE II 
RECEIPT AND SUPERVISION OF MEDICATION 
Cohort 
Modecate : 
regularly received 63% 
Lithium : 
regularly received 79% 
Lithium assessed 68% 








C B Differences 
70% 47% W & C : B 
5/8 2/3 Too few for stats. 
2/8 1/3 Too few for stats. 
42% 27% C : W & B 
For the cohort as a whole two-thirds of those on modecate receive it 
regularly, but less than half of the Blacks (who were actually prescribed 
modecate more often) received it regularly. Medication is supervised in 
only one-third of patients. This is an important factor leading to poor 
compliance. 
DIFFERENCES 
0 Modecate : 
Significantly less Blacks receive their modecate than Whites and 
Coloureds. i.e. those who are prescribed the most, get it the least. 
Further breakdown of the data shows that, of those Blacks who have 







NOT AT ALL 
28% 
Too few patients were prescribed lithium for significant statistical 
analysis but most Whites on Lithium received and had it assessed 
regularly (15/17). 
0 Supervision : 
Interestingly significantly more Coloureds had their medication 
supervised, probably because of the social conditions whereby they are 
more likely to be living with the extended family, whereas Whites live 
alone, as do the Blacks - many of whom are in Cape Town without 
families. 
3) Awareness of Treatment and Regime 
TABLE III 
AWARENESS OF TREATMENT AND REGIME 
(Percentage frequencies) 
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Whole w C B Differences cohort 
Awareness of next appointment 62 83 63 42 w : C : B 
Awareness of treatment regime ~- 60 80 65 34 W & C : B 
Awareness of what pills are for* 76 90 82 57 W & C : B 
*Figures refer to "good" awareness only. 
+Figures include "mod" and "good" awareness i.e. "nerves" as well as full 
explanation. 
(Full awareness 72% W to 13% C 13% b; p 0,001) 
TABLE III 
For the cohort as a whole, approximately two-thirds were aware of their 
next appointment and their treatment regimes. Three-quarters knew what 
the pills were for. (Patients were classified as having moderate aware-
ness if they said the pills were for "nerves"). 
DIFFERENCES : 
0 Appointment : 
The awareness of next appointment was significantly different between all 
the race groups. 
0 Regimen : 
Only one-third of the Blacks knew how to take their pills. This has 
serious implications as far as treatment efficiency is concerned. It 
appears that Blacks as a group are not assimilating these instructions, 
and there are many possible reasons for this, including : 
1) Not being told correctly 
2) Not understanding instructions 
3) Viewing the illness differently from the other groups. 
This aspect of poor compliance needs further assessment. 
~Compliance : 
There are 4 measures of compliance and each will be presented in turn. 
a) Family opinion 
TABLE IV 















By this measure, just over half of the cohort are complying, but there 
are significant differences between all the groups. 
TABLE V 
COMPLIANCE : 2. PILL COUNT 
(Percentage frequencies) 
This applies only to those on pills (actually almost everyone). 
Interviewers checked pills at home. 
Good Mod + Poor 
Cohort 52 48 
w 75 25 
C 50 50 
B 33 67 
Differences w C B 
TABLE V 
These figures are almost the same as for family opinion, with identical 
significant differences. 
TABLE VI 
COMPLIANCE : 3. URINE 
(Percentage frequencies) 
Only applies to those on Oral Phenothiazines. 
Good Mod+ Poor 
Cohort 51 49 
w 74 26 
C 56 44 
B 32 68 
Differences B C & W 
TABLE VI 
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Exactly the same pattern as before (except level of significance changes 
slightly for the Coloureds). 
TABLE VII 
COMPLIANCE : 4. INTERVIEWER ASSESSMENT 
(Percentage frequencies) 
This is a GLOBAL assessment taking all the above factors into account, 
i.e. family opinion, pill count, urine test as well as overall impression. 
Good Mod+ Poor 
Cohort so so 
w 73 27 
C 47 53 
B 31 69 
Differences w C B 
TABLE VII 
The interviewer's subjective impression corresponds with the other measures, 
and although it cannot be said which measure is the most reliable, this method 
takes all the factors into account. 
The inter-racial differences are all statistically significant and have im-
portant implications as regards waste of money and unused medication lying 
around. 
TABLE VIII 
REASONS FOR NOT COMPLYING 
(Percentage frequencies) 
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Applies to those the interviewer felt were not complying or were complying 
poorly. Items are NOT mutually exclusive and to some extent overlap. 
Reasons w C B Difference 
(N = 29) (N = 48) (N = 75) 
Regimen ignorance 7 62 50 w : C & B 
Side effects 57 37 42 -
Resistance 83 90 84 -
Interference 3 4 4 -
Stigma 7 13 0 -
Tabs not received 0 0 0 -
Didn't attend 62 94 81 w : C 
No bus fare 0 0 3 NS 
0 Most important reasons given by all 3 groups : resistance and did not attend. 
0 The interesting thing is that C & B claimed ignorance, yet very few W did 
(ties in with compliance results). 
0 Important : no one said they did not receive their tablets. 
0 Difference between W & C as 94% C did not attend (that is more than B) but 
overlaps with other measures too - it is suspected that the higher prevalence 
of substance abuse is linked to this high percentage. 
SUMMARY OF RESULTS 
Significant racial differences were show~ in respect of all aspects of compliance, 
with the element of active resistance to treatment being more prevalent in the 
Coloureds and Blacks, as shown by the higher rate of "failure to attend". 
CONCLUSIONS 
The four measures of compliance confirm that drug defaulting is a problem in the 
Cape situation comparable to the worst assessed elsewhere (predominantly Britain 
and the USA). 
Approximately only 50% of the whole Valkenberg Cohort were good compliers. 
Blackwell (1973) found that the studies to date for the U.S.A. produced figures 
ranging from 25 - 50% poor compliance. 
Our study confirmed the supposition that compliance is poorer amongst Blacks 
compared with Whites, though this findings applies to the heterogeneous groups 
as a whole and is only the first step in assessing the role of non-compliance 
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in relapse and re-admission. The reasons given for poor compliance were only 
superficially assessed but the very significant difference between the Whites and 
the other groups as regards ignorance of the medication regimens, is something 
that can be worked on immediately, with a little further study to assess exactly 
the level of information communication breakdown. The element of active re-
sistance to treatment is the same across all race groups and it seems likely that 
the factor of "uncooperative personality" is the same for all groups and is 
probably similar the world over, as the figures for compliance in the Whites are 
closest to the average reported in the literature (which is basically concerned 
with a similar socio-cultural group). 
The finding that no patients claimed not to have received their medication is 
gratifying and indicative that the current distribution 5ystem is adequate and 
efficient. 
These initial findings are enough to indicate that there is a compliance problem 
and that it is a significant one, however it is hoped that the intentional and 
unintentional aspects of poor compliance in the Cape setting, will be further 
elucidated following the correlation of patient variables such as age, sex and 
diagnosis. 
It is hypothesised that, following this manoevre, the widely differing rates for 
good compliance shown by each race group will be seen to be due mainly to ignor-
ance by Blacks, of all the facets of psychiatric illness culturally assimilated 
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Appendix A 





Is patient on Modecate? 
If Yes : 
+ Patient receives Modecate regularly 
Patient receives Modecate irregularly 
Patient has not received Modecate 
Is patient on Lithium? 
If Yes : 
Has Lithium level been assessed regularly? 
+ Patient receives Lithium regularly 
Patient receives Lithium irregularly 
Patient has not received Lithium 
Is patient/ family aware of the next appointment? 
Is the patient's medication supervised? 
If Yes 
+ Medication is always supervised 
Medication is sometimes supervised 
Medication is not supervised 
5. Does patient/ person administering the tablets know 
how many different sorts of tablets he has to take, their 










In the opinion of the family, does the patient comply with 
his medication? 








Yes ( 2) 
No (1) ( 
Yes ( 2) 




Yes ( 2) 
No (1) ( 
Yes ( 2) 



























After counting left-over pills, the interviewer should 
rate whether there was -




From patients on Phenothiazine 
+ Good compliance 
Moderate compliance 
Poor compliance 
If poor/ no compliance (Specify patient's reasons) 
Yes No 
Ignorance of regime (2) (1) 
Side effects of medication (2) (1) 
Active resistance by patient (2) (1) 
Outside pressure / advice (2) (1) 
Stigma of mental illness (2) (1) 
Tablets not received (2) (1) 
Did not attend clinic (2) (1) 


























. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
9. Interviewer assessment of overall compliance : 
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APPENDIX B 
THE FORREST TEST 
In the late 1950's Drs. Fred and Irene Forrest of the Veterans Administration 
Hospital, Palo Alto, California, developed a series of tests designed to show 
the presence of Phenothiazine derivatives in the urine. The search for a 
suitable test stemmed directly from the need to assess whether or not the patients 
were taking their medication. (The 20 original papers on this research are suc-
cinctly reviewed in Forrest et al - (1961) ). 
During their early work into the metabolic fate of phenothiazine compounds, some 
incidental observations indicated that chlorpromazine had a very reactive nucleus 
tending to produce a variety of oxidative derivatives. These observations in-
cluded the obvious autoxidation of aqueous chlorpromazine solutions, rapidly 
turning brown when exposed to daylight, and the photosensitivity of patients on 
chlorpromazine therapy. Assuming that some of the more reactive intermediates 
might be demonstrable in the urine, a search for a simple suitable reagent was 
started and resulted in the first rapid urine color test for chlorpromazine 
being developed in 1957, whereby an acid solution of Ferric Chloride, mixed with 
urine, yielded a scale of purple colours proportionate to drug intake. A subse-
quent search of the literature showed that whereas there were few pertinent data 
for chlorpromazine, there was a vast body of literature for the parent compound 
Phenothiazine. The entire Phenothiazine field from its synthesis by Bernthsen 
in 1883 to that time, the 1950's including all industrial and pharmacologic 
applications had been comprehensively and competently reviewed by Massie (1954). 
Animal studies on the metabolism and excretion of phenothiazine showed that the 
type and amount of drug metabolites varied from species to species, but that the 
urines contained one or more partially oxidised or hydroxylated intermediary 
metabolites in all instances. (De Eds 1938, Collier 1940, De Eds 1940, 
Clare 1947). The first basic metabolic data for chlorpromazine were reported 
by Salzman et al. (1955). They identified, in human urine, the chemically 
unchanged, unoxidised chlorpromazine and its sulfoxide. These 2 compounds 
essentially the beginning and the end of the human metabolic process account 
for only 5 - 12% of the daily drug dose, hence a large balance is left unac-
counted for. Furthermore neither of these 2 compounds is responsible for the 
intense purple color reactions, as unoxidised chlorpromazine yields a pink 
colour, white sulfoxide produces no colour at all with the original test 
reagent. 
Forrest and co-workers speculated that the partially oxidised, highly reactive 
intermediary drug metabolites might act as oxido-reduction systems and tried to 
duplicate the physiological metabolism of chlorpromazine in vitro by ultra-
violet irradiation of aqueous drug solutions (Forrest et al. 1958). While this 
did not produce any sulfoxide, it did lead to the formation of an oxidative 
intermediate closely resembling the urinary metabolites responsible for the 
colour test. While continuing to investigate the chemical nature of the elusive 
intermediates, the initial rapid urine colour test for chlorpromazine was modi-
fied for the purpose of demonstrating other urinary phenothiazine drugs and to 
provide objective criteria for their intake. Initially 7 separate tests were 
developed, later streamlined to 4, including the ''FPN'' Universal Test Reagent 
that was used in the Valkenberg Compliance Study. 

























20 parts 5% 
Ferric Chloride. 
80 parts 10% 
Sulphuric Acid. 
Same as above. 
2 parts 5% 
Ferric Chloride. 
98 parts 30% 
Sulphuric Acid. 
25 parts 0,2% 
Potassium Dichro-
mate. 
25 parts 30% 
Sulphuric Acid. 
25 parts 20% 
Perchloric Acid. 




5 parts 5% 
Ferric Chloride. 
45 parts 20% 
Perchloric Acid. 
SO parts 50% 
Nitric Acid. 
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PERFORMANCE OF TEST 
Mix 1 ml urine with 
1 ml solution. 
Read promptly. 
Same as above, 
(but colour range is 
darker). 
Mix 1 ml urine with 
1 ml solution. 
Read within 20 
seconds. 
Mix 0,5 mls urine 
with 1 ml solution. 
Read promptly. 
Mix 1 ml urine with 
1 ml solu.tion. 
Read immediately. 
Disregard all colours 
appearing after a 
delay of 10 seconds 
or more. 
A positive result in each case indicated by the appearance of variable shades of 
blue, the intensity of which; roughly correlates with the daily dosage intake of 
phenothiazine. 
The Forrest Reagents are cheap to produce and stable for long periods in light 
proof bottles. The test has been validated in independent studies by Pollack 
(1958). 
It is interesting that there is no literature concerning the Forrest test 
appearing after 1961. The test was developed for the express purpose of check-
ing on patient compliance, was in vogue for a few years and then shelved for 
reasons that are purely speculative. 
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